Clinical trial NCT00613418: Comparative Study Of Safety And Efficacy Of The SUPERA® Nitinol Stent - Iliac Artery
Official title: Comparative Study of Safety and Efficacy of the SUPERA® Wire Interwoven Self-expanding Nitinol Stent and Currently Approved Stents for Patients With Iliac Lesions
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: With de Novo or Restenotic Lesions in the Common and/or External Iliac Arteries
Lead sponsor: Abbott Medical Devices
Sponsor class: INDUSTRY
Collaborators: name: Baim Institute for Clinical Research
First posted: 2008-02-13
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a prospective, multicenter, non-randomized, single-arm trial; the primary objective is to assess the comparability of the performance of the IDev SUPERA® nitinol stent to a rate derived from a meta-analysis of studies on iliac stents approved by FDA for treating subjects with de novo or restenotic lesions in the common and/or external iliac arteries.


Eligibility criteria: Inclusion Criteria:

1. Subject is 18 years of age or older and of legal age of consent.
2. Subject has lifestyle limiting claudication or rest pain (Rutherford-Becker scale 2, 3 or 4).
3. Subject has de novo or restenotic lesions in the common or external iliac artery.
4. Subject has single, bilateral or multiple target lesions that is (are) ≥ 50% stenosed by visual estimate.
5. The target lesion(s) can be successfully crossed with a guide wire and dilated.
6. The target segment of subject's lesion(s) is between 4 and 10 mm in diameter and less than 110 mm in length.
7. Subject has angiographic evidence of a patent femoral outflow artery in the target limb.
8. Subject has provided written informed consent.
9. Subject is able and willing to adhere to the required follow-up visits and testing through month 36.
10. Subject is able and willing to adhere to the required follow-up medication regimen

    -

Exclusion Criteria:

1. Presence of other non-target arterial lesions requiring treatment within 30 days of the procedure.
2. The target lesion(s) has adjacent, acute thrombus.
3. The target lesion(s) is highly calcified or was previously treated with a stent.
4. Subject has a pre-existing target iliac artery perforation or dissection of the target iliac artery prior to initiation of the IDev implant procedure.
5. Subject has an abdominal aortic aneurysm contiguous with the iliac artery target lesion. Subject has a pre-existing aneurysm or dissection of the target iliac segment.
6. Subject with aortic or iliac aneurysm that is likely to require repair within the next 9 months.
7. Subject has a post-surgical stenosis and anastomotic suture treatments of the target vessel.
8. Subject has a vascular graft previously implanted in the native iliac vessel.
9. Subject has tissue loss, defined as Rutherford-Becker classification category 5 or 6.
10. Subject is unable to accommodate ≥ 7 Fr cat
11. Subject has contrast agent hypersensitivity that cannot be adequately pre-medicated, has a hypersensitivity to nickel, or has intolerance to antiplatelet, anticoagulant, or thrombolytic medications.
12. Subject has history of neutropenia (WBC \<3,000/mm3).
13. Subject has coagulopathy or thrombocytopenia (platelet count \<80,000/ μL) that has not resolved or has required treatment in the past 6 months.
14. Subject has known bleeding or hypercoagulability disorder or significant anemia (Hb \< 8.0 g/dL) that cannot be corrected.
15. Subject has the following laboratory values:

    1. international normalized ratio (INR) greater than 1.5,
    2. serum creatinine level greater than 2.5 mg/dL.
16. Subject requires general anesthesia for the procedure.
17. Subject is pregnant or plans to become pregnant during the study.
18. Subject has a co-morbid illness that may result in a life expectancy of less than 1 year.
19. Subject is participating in an investigational study of a new drug, biologic or device at the time of study screening. NOTE: Subjects who are participating in the long term follow-up phase of a previously investigational and now FDA-approved product are not excluded by this criterion.

    -

Primary outcomes:
measure: Occurrence of death
timeFrame: within 30 days post-procedure
measure: Target site revascularization or restenosis
timeFrame: 9 months
Secondary outcomes:
measure: Major adverse events (MAEs)
timeFrame: 30 days
measure: Device success (delivery and deployment of the study stent and retrieval of the delivery system)
timeFrame: During implantation procedure
measure: Acute procedural success
timeFrame: immediately following stent deployment
measure: Early and late clinical success (Rutherford-Becker improvement); ABI and TBI improvement; symptom based.
timeFrame: 30 days and 6, 9, and 12 months
measure: Target vessel patency
timeFrame: 6, 9, 12, 24, and 36 months
measure: Quality of Life questionnaire
timeFrame: baseline, 3 and 6 months
Other outcomes:
Locations:
Study officials:
References: